Most Read Articles
Jairia Dela Cruz, 6 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, Yesterday
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.

Product Highlight - Forxiga

26 Jun 2020

In DECLARE TIMI-58:
Forxiga has shown to provide early CARDIORENAL benefits beyond HbA1c reduction in T2DM patients across CV risks1,2,3

  • Reduce the risk of hospitalization for heart failure compared to placebo by 27%.1
  • Reduce the risk of progression to nephropathy compared to placebo by 47%.2^
  • Well established safety profile compared to placebo.1,2
  • Superior reduction of glycaemic control compared to DPP4i with additional benefit of weight loss and BP reduction.3,4*

^Forxiga is not indicated for the treatment of heart failure and chronic kidney disease.
* Forxiga is not indicated for the management of weight loss or high blood pressure. Weight change was a secondary endpoint in clinical trials. Blood pressure change was primarily assessed as a safety or exploratory endpoint.


References:
1. Wiviott SD et.al. N Engl J Med. 2019; 380(4):347-357.
2. Mosenzon O et.al. The Lancet Diabetes & Endocrinology 2019 Aug 7(8):606-617.
3. Rosenstock J, et al. Presented at WCIRDC 2016 Poster 99.
4. Rosenstock J et.al. Arch Endocrinol Metab. 2018;62(4):424-430.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 6 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, Yesterday
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.